Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170624 | 0.86 | HDAC1 (0.69) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 | |
| SCHEMBL2491503 | 0.85 | MAPT (0.68) | KEAP1HDAC2HDAC8HDAC6TDP1 | |
| SCHEMBL3244035 | 0.83 | MAPT (0.71) | HDAC2HDAC8HDAC6TDP1HDAC1 | |
| SCHEMBL9129396 | 0.83 | MAPT (0.71) | HDAC2HDAC8HDAC6TDP1HDAC1 | |
| SCHEMBL6561091 | 0.83 | MAPT (0.71) | HDAC2HDAC8HDAC6TDP1HDAC1 | |
| SCHEMBL3450605 | 0.81 | KEAP1 (0.67) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 | |
| SCHEMBL497371 | 0.80 | KEAP1 (0.73) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 | |
| Phenyl Propionic Acid SCHEMBL3419 | 0.80 | KEAP1 (1.00) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 | |
| Phenyl Propionic Acid SCHEMBL29619843 | 0.80 | KEAP1 (1.00) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 | |
| Phenyl Propionic Acid SCHEMBL13618844 | 0.80 | KEAP1 (1.00) | KEAP1FFAR1ALDH1A1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | claimed |
| WO-2012175513-A1 | THIENYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | claimed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | claimed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | claimed |
| EP-2378880-A1 | USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-10-26 | — | — | EP | claimed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | claimed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | claimed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0421365-B1 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | WAKAMOTO PHARMA CO LTD (JP) | 1997-03-05 | — | — | EP | claimed |
| US-RE35321-E | ANTIDIABETIC AGENT | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | claimed |
| US-5158959-A | Treatment of hypertension | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | claimed |
| EP-0316820-B1 | THIAZOLE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-22 | — | — | EP | claimed |
| US-5068239-A | Antidiabetic agent | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0421365-A2 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1991-04-10 | — | — | EP | claimed |
| US-4921887-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-01 | — | — | US | claimed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | claimed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286127-A1 | ANTITUMOR AGENT | BRDT, HDAC1, BRPF3 | KEAP1 1284/4885FFAR1 4106/4885ALDH1A1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.